Ardelyx (ARDX)
(Delayed Data from NSDQ)
$5.55 USD
-0.53 (-8.72%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $5.56 +0.01 (0.18%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARDX 5.55 -0.53(-8.72%)
Will ARDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARDX
Here's What Key Metrics Tell Us About Ardelyx (ARDX) Q2 Earnings
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
ARDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
Other News for ARDX
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)
Ardelyx: Strong Sales Growth and Strategic Expansion Drive Buy Rating
Ardelyx price target raised by $1 at H.C. Wainwright, here's why
Ardelyx Faces Rising Challenges Despite Revenue Growth
What 6 Analyst Ratings Have To Say About Ardelyx